Freedom of Information Act Requests related to Coronavirus/COVID-19

Below are Freedom of Information Act (FOIA) requests filed by KEI related to issues concerning the coronavirus/COVID-19 pandemic. This page will be updated as we file requests and receive responses.

 

Department of Health and Human Services

Centers for Disease Control and Prevention (CDC)

  • Filed March 20, 2020. Records related to remdesivir grant. STATUS: Awaiting acknowledgement.

Biomedical Advanced Research and Development Authority (BARDA)

  • Filed March 20, 2020. Records related to remdesivir grant. STATUS: Awaiting acknowledgement.
  • Filed March 25, 2020. Records concerning “Other Transaction Authority” contract with Johnson&Johnson for novel coronavirus vaccine. STATUS: Awaiting Acknowledgement.
  • Filed March 25, 2020. Records concerning “Other Transaction Authority” contract with Regeneron Bio for novel coronavirus vaccine. STATUS: Awaiting Acknowledgement.

Food and Drug Administration (FDA)

  • Filed March 25, 2020. Records concerning Gilead Sciences’ remdesivir orphan drug designation application and FDA’s review of the application. STATUS: Awaiting Acknowledgement.

National Cancer Institute (NCI)

  • Filed March 20, 2020. Records related to remdesivir grant. STATUS: Final response received March 23, 2020. Records under review by KEI.

National Institute of Allergy and Infectious Diseases (NIAID)

  • Filed March 20, 2020. Records related to remdesivir grant. STATUS: Acknowledged March 20, 2020.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

  • Filed March 20, 2020. Records related to remdesivir grant. STATUS: Acknowledged March 20, 2020.

 

Department of Defense

United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

  • Filed March 23, 2020. Records related to remdesivir grant. STATUS: Awaiting acknowledgement.

Defense Health Agency (DHA)

  • Filed March 25, 2020. Records related to Ology Bioservices contract with DoD via Defense Health Agency to work with Inovio Pharmaceuticals to manufacture a COVID-19 DNA vaccine. STATUS: Awaiting Acknowledgement.

 

For more on KEI’s work on COVID-19, see keonline.org/coronavirus.